Apeiron Biologics AG
http://www.apeiron-biologics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Apeiron Biologics AG
Ligand Makes Second Big Oncology Investment In 2024 With Apeiron Buyout
The company is acquiring rights to royalties from Qarziba, a neuroblastoma drug approved in ex-US markets that Recordati develops and markets in all of them except mainland China.
AI Driving Innovation: Insights From Exscientia CEO Andrew Hopkins
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.
Coronavirus Notebook: EMA Begins Assessing AZ’s Evusheld, Apeiron Starts Phase I Trial Of Inhaled APN01
The UK has explained its strategy for administering COVID-19 vaccines to people who have been partially immunized abroad.
Coronavirus Notebook: UK Begins COVID-19 Vaccine Rollout, Government May Enlist Military Backup
EU passes legislation allowing VAT exemption for coronavirus vaccines to make them more affordable, as two treatments for severe disease and “Long COVID” respectively enter Phase II trials.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Liposomes
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- invIOs GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice